Under the agreement, UMN Pharma and its subsidiary, UNIGEN, will use Catalent’s GPEx technology for producing a number of biosimilars.
UMN Pharma said for product development including clinical trials, marketing and sales, it is separately forming an alliance with pharmaceutical companies.
In addition, UMN Pharma is planning to initiate multiple biosimilar projects with the alliance companies for the Asian market on an ongoing basis.
Catalent business unit president Barry Littlejohns said, "This agreement will allow Catalent to continue to grow its biologics development and manufacturing interests of multiple biosimilars and NBEs, particularly in the Asian market."
Catalent Japan president Hans-Joachim Rohe said, "We are very excited to offer a continuously expanding range of Catalent services to our customers in Japan."